What caused the sharp rise in 4594.T stock today?

Heavy trading and speculative buying around BrightPath’s clinical pipeline drove the jump. Volume reached 80,455,900 shares, far above average, suggesting retail-driven momentum rather than a confirmed earnings surprise.

How does BrightPath’s valuation compare to peers?

BrightPath shows negative earnings (EPS -11.54) and a negative PE. Price-to-book is 4.31 versus the healthcare sector average around 2.27. The company trades at a premium on PB despite operating losses.

What is Meyka AI’s current view on 4594.T stock?

Meyka AI rates 4594.T **65.10/100** (Grade B, HOLD). The model highlights high volatility and pipeline risk. Forecasts show a monthly projection of **JPY 59.56**, and forecasts are model-based projections, not guarantees.

Should I buy 4594.T stock after the surge?

This is a speculative situation. The price is up sharply on heavy volume while fundamentals remain weak. Investors should wait for confirmed clinical updates or improved financials before increasing exposure.

JP Stocks

4594.T stock up 36.36% to JPY 75 on JPX 19 Jan 2026: what drove the jump

ByDanny Kontos January 19, 2026

The 4594.T stock surged 36.36% to JPY 75.00 on the JPX on 19 Jan 2026 on unusually heavy trading. Volume hit 80,455,900 shares, well above the 50-day average of 1,813,091. The move followed clinical and pipeline chatter for BrightPath Biotherapeutics Co., Ltd. (4594.T) and renewed speculative buying in small-cap biotech names in Japan. We outline drivers, valuation, technicals, and what Meyka AI’s models project next.